By use of chemical enablement and prospective design, a novel series of selective, brain penetrant PDE9A inhibitors have been identified that are capable of producing in vivo elevations of brain cGMP.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1021/jm9015334 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!